Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
M. Masson Regnault, Jason Shourick, Fatma Jendoubi, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 433-447
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 127
Inflammatory memory in psoriasis: From remission to recurrence
Luc Francis, Francesca Capon, Catherine Smith, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 42-50
Open Access | Times Cited: 12
An Approach for Psoriasis of Microneedle Patch Simultaneously Targeting Multiple Inflammatory Cytokines and Relapse Related T Cells
Li Huang, Ying Luo, Le Kuai, et al.
Biomaterials (2025), pp. 123120-123120
Closed Access | Times Cited: 1
The role of microRNA in psoriasis: A review
Xingyu Jiang, Rongcan Shi, Rui Ma, et al.
Experimental Dermatology (2023) Vol. 32, Iss. 10, pp. 1598-1612
Open Access | Times Cited: 18
The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris
Jaehwan Kim, Ariana Moreno, James G. Krueger
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Resident cutaneous memory T cells: a clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets
James P. Pham, Kirsty Wark, Jane Woods, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 6, pp. 656-663
Closed Access | Times Cited: 13
Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation
Pedro Herranz, M.L. Alonso‐Pacheco, Rosa Feltes, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 7, pp. 517-527
Open Access | Times Cited: 11
Generation of Activated CD8 +  Tissue-Resident Memory T Cells Requires Cross-Priming by CLEC9A +  Dendritic Cells During Psoriatic Chronicity
Yun Luo, Xiaoyan Wu, Leying Liu, et al.
(2025)
Closed Access
Immune Memory: A New Frontier in Treating Recurrent Inflammatory Skin Diseases
Hang Yin, Jianru Chen, Chunying Li
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Closed Access
Personalized prediction of psoriasis relapse post-biologic discontinuation: a machine learning-driven population cohort study
Shan Huang, Yanping Bai, Ruili Qi, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Chinese herbal medicine (Guben Qushi Huayu formula) combined with Ixekizumab in reducing psoriasis vulgaris relapse: Protocol for a mixed-methods research study
Ziqing Li, Kun‐Liang Guan, Hao Deng, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab
Hanwen Wu, Jiling Zhu, Nali Yang, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2025)
Closed Access
Diagnostic dilemma of a new endobronchial lesion in a patient on anti-tuberculosis regimen: unveiling tuberculosis immune reconstitution inflammatory syndrome
Ming Ren Toh, Sophie Seine Xuan Tan, Takano Angela, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®)
A. Dernoncourt, Sophie Liabeuf, Youssef Bennis, et al.
BioDrugs (2022) Vol. 37, Iss. 1, pp. 73-87
Open Access | Times Cited: 15
d-mannose blocks the interaction between keratinocytes and Th17 cells to alleviate psoriasis by inhibiting HIF-1α/CCL20 in mice
Qian Jiang, Benliang Wei, Mengshu You, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110087-110087
Closed Access | Times Cited: 9
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Giampiero Girolomoni, L. Savage, Paolo Gisondi, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2171-2185
Open Access | Times Cited: 8
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective
Gabriele Roccuzzo, Eleonora Gherardi, Michele Maio, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 125-131
Closed Access | Times Cited: 2
Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study
Shan Huang, Xingwu Duan, H Zhang, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Functional Genomics in Psoriasis
Stefano Rossi, Ellie Richards, Gisela Orozco, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7349-7349
Open Access | Times Cited: 2
Belgian recommendations for managing psoriasis in a changing treatment landscape
Reinhart Speeckaert, Arjen Nikkels, Jo Lambert, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 2
Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military
Alexius Russell, Samantha Williamson, Alexandra Rosenberg, et al.
Military Medicine (2024) Vol. 189, Iss. 11-12, pp. e2374-e2381
Open Access | Times Cited: 1
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
Chang‐Yu Hsieh, Francis Li‐Tien Hsu, Tsen‐Fang Tsai
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2607-2620
Open Access | Times Cited: 1
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study
Yu-Huei Huang, Sung‐Jen Hung, Chaw‐Ning Lee, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 6, pp. 997-1008
Closed Access | Times Cited: 1
Skin-resident T Cells Contribute to the Dynamic Disease Manifestations of Psoriasis
Daniel Sortebech, Trine Schoenfeldt, Albert Duvetorp, et al.
The Journal of Immunology (2024) Vol. 213, Iss. 9, pp. 1267-1277
Closed Access | Times Cited: 1
IL-17 and -23 Inhibitors for the Treatment of Psoriasis
Sonali Batta, Ramlah Khan, Marcus Zaayman, et al.
EMJ Allergy & Immunology (2023)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top